Project Grant R01AR086572
Award Date
7/5/25
Completion Date
6/30/30
Dollars Obligated
$667K
Federal Grant Program
93.846
Assistance Type
Project Grant
Place of Performance
Worcester, MA 01655, USA
Similar Awards
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $221,100 Project Grant (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) to the University of Massachusetts Medical School to develop and evaluate in vivo gene editing strategies to repair collagen mutations in mouse models of osteogenesis imperfecta (OI). The 2-year project aims to use bone-targeting recombinant adeno-associated virus (rAAV) to implement precise gene editing...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will support research focused on developing a cellular therapy approach to treat osteogenesis imperfecta (OI), a genetic disease that causes bone fragility. The $386,481 award to the University of Connecticut Health Center (UCHC) will fund a 5-year research project to evaluate different cell...
This $159,594 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), supports research to identify new therapeutic targets for osteogenesis imperfecta (OI), a rare genetic bone disorder. The award recipient, the Research Foundation of the City University of New York (RFCUNY), will investigate the intracellular signaling and extracellular matrix mechanisms...
This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under CFDA 93.846 Arthritis, Musculoskeletal and Skin Diseases Research, will develop a novel gene therapy for bone healing. The $454,050 grant will fund research to use an adeno-associated virus (AAV) vector to deliver bone morphogenetic protein-2 (BMP-2) and interleukin-1 receptor antagonist (IL-1RA) to heal critical size osseous defects in a validated rat model. The...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $395,537 to Brigham & Women's Hospital Inc. to develop and validate CRISPR-based genome editing strategies to correct genetic mutations in the CLCN7 gene that cause osteopetrosis, a rare and debilitating skeletal disorder. The project aims to optimize genome editing techniques in...
This $313,000 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) will fund research by Emory University to establish phosphorylated WNT5A produced by osteoclasts as a potential anabolic bone drug. The research aims to determine how osteoclast-derived phospho-WNT5A can enhance bone formation in vivo and elucidate the cellular and molecular mechanisms by...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $123,040 Project Grant under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to the University of Kansas Medical Center Research Institute, Inc. (KUMCRI) to investigate the therapeutic role of the NFAT1 transcription factor in osteoarthritis. The 5-year project, which began on August 1, 2024, aims to evaluate the potential of AAV-delivered NFAT1 gene therapy in treating...
This $589,255 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) aims to develop small RNA targeting approaches, such as microRNA and siRNA, to advance treatments for heterotopic ossification (HO). HO is a condition involving pathologic bone formation in soft tissues that can occur following orthopedic surgeries or injuries. The award will fund the...
This Project Grant award of $1,150,474 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) supports research to explore the cellular and molecular mechanisms driving large-scale bone regeneration. The research aims to unravel the intricate events necessary for extensive bone repair by investigating the role of a sentinel-type cell population marked by SOX9 expression in...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $1,066,302 Project Grant under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to the University of Massachusetts Medical School. The grant, effective April 1, 2025 through March 31, 2029, will fund the creation of a biomedical knowledgebase to promote and facilitate the use of the Osteoarthritis Initiative (OAI), a rich 16-year observational study with comprehensive...